CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
REVENUES:
Net product revenues	$ 302,190	$ 235,357
Royalty and other revenues	1,555	1,379
Total revenues	303,745	236,736
OPERATING EXPENSES:
Cost of sales	50,006	43,118
Research and development	145,003	158,793
Selling, general and administrative	120,019	105,300
Intangible asset amortization and contingent consideration	8,925	10,442
Total operating expenses	323,953	317,653
LOSS FROM OPERATIONS	(20,208)	(80,917)
Equity in the loss of BioMarin/Genzyme LLC	(523)	(135)
Interest income	3,072	1,571
Interest expense	(10,119)	(9,843)
Other income	3,472	198
LOSS BEFORE INCOME TAXES	(24,306)	(89,126)
Benefit from income taxes	(8,016)	(6,075)
NET LOSS	$ (16,290)	$ (83,051)
NET LOSS PER SHARE, BASIC AND DILUTED	$ (0.09)	$ (0.51)
Weighted average common shares outstanding, basic and diluted	172,710	161,548
COMPREHENSIVE LOSS	$ (24,086)	$ (104,037)